US20050101012A1 - CD4+CD25+ regulatory T cells from human blood - Google Patents
CD4+CD25+ regulatory T cells from human blood Download PDFInfo
- Publication number
- US20050101012A1 US20050101012A1 US10/661,804 US66180403A US2005101012A1 US 20050101012 A1 US20050101012 A1 US 20050101012A1 US 66180403 A US66180403 A US 66180403A US 2005101012 A1 US2005101012 A1 US 2005101012A1
- Authority
- US
- United States
- Prior art keywords
- cells
- agent
- vivo
- regulatory
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 title claims abstract description 217
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 title claims abstract description 217
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 title claims abstract description 217
- 210000003289 regulatory T cell Anatomy 0.000 title claims description 24
- 241000282414 Homo sapiens Species 0.000 title claims description 19
- 210000004369 blood Anatomy 0.000 title claims description 14
- 239000008280 blood Substances 0.000 title claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 304
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000001105 regulatory effect Effects 0.000 claims abstract description 31
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 72
- 210000004443 dendritic cell Anatomy 0.000 claims description 69
- 239000000427 antigen Substances 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091008874 T cell receptors Proteins 0.000 claims description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 29
- 108010002350 Interleukin-2 Proteins 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 24
- 102000003814 Interleukin-10 Human genes 0.000 claims description 20
- 108090000174 Interleukin-10 Proteins 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 239000002269 analeptic agent Substances 0.000 claims description 13
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 12
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 10
- 208000024908 graft versus host disease Diseases 0.000 claims description 10
- 238000002054 transplantation Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 230000001640 apoptogenic effect Effects 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 230000000961 alloantigen Effects 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- -1 but not limited to Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000009760 functional impairment Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000002483 superagonistic effect Effects 0.000 claims description 3
- 102000007577 Desmoglein 3 Human genes 0.000 claims description 2
- 108010032035 Desmoglein 3 Proteins 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108010002335 Interleukin-9 Proteins 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000001338 necrotic effect Effects 0.000 claims description 2
- 239000002644 phorbol ester Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 238000007885 magnetic separation Methods 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 240
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 240
- 230000035755 proliferation Effects 0.000 description 32
- 102000000588 Interleukin-2 Human genes 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 26
- 230000000735 allogeneic effect Effects 0.000 description 25
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 20
- 102000003812 Interleukin-15 Human genes 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 16
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930191564 Monensin Natural products 0.000 description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 229960005358 monensin Drugs 0.000 description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Definitions
- the present invention provides suppressive and/or regulative human CD4 + CD25 + T cells, a method for expanding same, and the use of the suppressive and/or regulative human CD4 + CD25 + T cells and of the corresponding expanded T cells as regulatory agent.
- Immunological self-tolerance is critical for the prevention of autoimmunity and maintenance of immune homeostasis.
- the ability of the immune system to discriminate between self and non-self is controlled by mechanisms of central and peripheral tolerance.
- Central tolerance involves deletion of self-reactive T lymphocytes in the thymus at an early stage of development (Rocha, B. and von Boehmer, H., Science 251:1225-1228 (1991); Kisielow, P. et al., Nature 333:742-746 (1988)).
- Several mechanisms of peripheral tolerance have been described, including T cell anergy and ignorance (Rocha, B. and von Boehmer, H., Science 251:1225-1228 (1991); Kisielow, P.
- CD4 + CD25 + regulatory T cells constitute a rather homogenous population (Thornton, A. M., Shevach, E. M., J. Immunol. 164:183-190 (2000)), are derived from the thymus (Itoh, M. et al., J. Immunol. 162:5317-5326 (1999)), are naturally non-proliferative (i.e. anergic) to stimulation via the TCR, but require activation via their TCR to become suppressive and to inhibit the proliferation of CD4 + or CD8 + T cells. Once activated, however, their regulatory/suppressor function was completely antigen-nonspecific, cytokine-independent yet cell contact dependent (Thornton, A.
- CD4 + CD25 + T cells inhibit the proliferation of responders by inhibiting their IL-2 production (Thornton, A. M., Shevach, E. M., J. Exp. Med. 188:287-296 (1998)).
- Recent in vivo studies suggest that the function of CD4 + CD25 + T cells is crucially dependent on signaling via the CTLA-4/CD152 molecule which was found to be constitutively expressed on CD4 + CD25 + T cells (Read, S.
- CD4 + CD25 + T cell population constitutes a unique lineage of “professional” regulatory/suppressor T cells which are crucial for the prevention of spontaneous autoimmune disease (Sakaguchi, S. et al., J. Immunol. 155:1151-1164 (1995)), it is unknown to date, whether CD4 + 4T cells exhibiting similar functional properties are naturally occurring in man.
- the removal and/or functional impairment of these cells in vivo in mice e.g. by anti-CD25 and/or anti-CTLA-A4 mAb treatment of animals induces various spontaneous autoimmune diseases AND rejection of tumors.
- the mechanism is that removal/impairment of these cells removes their negative control of autoreactive T cells so that these T cells become active. If one gives back the CD4 + CD25 + T cells by adoptive transfer into these animals regluation is restored and autoimmunity/tumor rejection is stopped.
- CD4 + CD25 + , primarly CD45RO + T cells (mean 6% of CD4 + T cells), hereinafter shortly referred to as “CD4 + CD25 + T cells”
- CD4 + CD25 + T cells are present in human blood, in particular the peripheral blood of adult healthy volunteers.
- T cells exhibiting the phenotype i.e., suppressive/regulatory CD4 + CD25 + T cells
- T cells exhibiting the phenotype i.e., suppressive/regulatory CD4 + CD25 + T cells
- T cells exhibiting the phenotype i.e., suppressive/regulatory CD4 + CD25 + T cells
- they were misinterpreted to be conventional memory cells Koreanegane, H. et al., Int. Immunol., 3:1349-1356 (1991); Taka, K. et al., Immunol. 72:15-19 (1990); Jackson, A. L. et al., Clin. Immunol.
- CD4 + CD25 + T cells are not conventional memory cells but rather regulatory cells exhibiting functional properties identical to their rodent counterparts.
- CTLA-4 (CD152) which is essential for the in vivo suppressive activity of CD4 + CD25 + T cells, was constitutively expressed, and remained strongly upregulated after stimulation. The cells were non-proliferative to stimulation via their TCR, but the anergic state was partially reversed by IL-2 and IL-15.
- CD4 + CD25 + T cells Upon stimulation with allogeneic (but not syngeneic) mature dendritic cells or plate-bound anti CD3+ anti-CD28 the CD4 + CD25 + T cells released IL-10, and in coculture experiments suppressed the activation and proliferation of CD4 + and CD8 + T cells. Suppression proved IL-10 independent, yet contact dependent as in the mouse.
- the identification of regulatory CD4 + CD25 + T cells has important implications for the study of tolerance in man, notably in the context of autoimmunity, transplantation, and cancer.
- the present invention provides
- FIG. 1 shows that CD4 + CD25 + T cells exhibit distinct phenotypical differences as compared to CD4 + CD25 ⁇ T cells.
- FIG. 2 shows that CD4 + CD25 + T cells are nonproliferative/anergic to both allogeneic and polyclonal stimulation, which is partially reversed by the addition of IL-2 and/or IL-15, but not by neutralizing anti IL-10 antibodies.
- FIG. 3 shows that CD4 + CD25 + T cells, if stimulated via the TCR, suppress the activation of CD4 + and CD8 + T cells in a cell contact- and dose-dependent manner.
- FIG. 4 shows that the cytokine profiles of CD4 + CD25 + and CD4 + CD25 ⁇ T cells are different.
- FIG. 5 shows that activated and fixated CD4 + CD25 + cells still exhibit regulatory capacity.
- Ligand or “ligands” in accordance with the present invention relates to all kinds of compounds capable of binding to specific molecules (including polynucleotides and polypeptides such as cell receptors, CD25, CTL-A4, etc.).
- a preferred ligand is a monoclonal antibody or a fragment thereof.
- the terms “ligand” and “antibody” are used interchangeable throughout the application text.
- Suitable APCs include autologous or non-autologous or artificial antigen-presenting cells (e.g. dendritic cells (for the preparation of dendritic cells see e.g. WO 93/20185, WO 97/29182 and EP-A-0 922 758), etc.).
- Said T cell stimulating agents and antigen-presenting cells can be used together with IL-2 or IL-15 or a combination thereof.
- IL-2/IL-15 other cytokines that use the gamma chain common to several cytokine receptors can also be used (including, but not restricted to, IL-7 and IL-9).
- IFN alpha and IL-10 which are known to promote the generation of other regulatory cells (Groux, H.
- T cell stimulation also promote the generation/expansion of these cells.
- other methods for polyclonal or oligoclonal e.g. by superantigens
- T cell stimulation anti-CD3 and/or anti-CD28 lingands/antigens including superagonistic antibodies; PMA+ ionomycin; etc.
- stimulating agents or antigen presenting cells may be used for the expansion in amounts well-known for a person skilled in the art.
- CD4 + CD25 + T cells also allows to monitor and expand CD4 + CD25 + T cells in vivo (e.g. by adminstering the T cells stimulating agents defined above, such as IL-2+IL-15 or IL-10+IFN ⁇ to patients, with or without the dendritic cells/antigen presenting cells) to induce regulatory T cells e.g. to fight autoimmune diseases.
- T cells stimulating agents defined above, such as IL-2+IL-15 or IL-10+IFN ⁇
- the CD4 + CD25 + T cells or expanded CD4 + CD25 + T cells of (1) or (3) above can be used in assays that will allow to identify other growth and/or functionally modifying (inhibitory/enhancing)/(apoptotic or anti-apoptotic) factors that can be used in vitro or in vivo (e.g. to stimulate or to remove or functionally disturb the CD4 + CD25 + T cells).
- T cells are also suitable for identifying molecules expressed by the CD4 + CD25 + T cells by methods such as but not restricted to mAb generation, proteomics, DNA chip analysis, subtractive hybridization (in particular (a) identification of “novel”, i.e., hitherto unknown, molecules, or (b) if these molecules are suitable pharmaceutical target structures, to therewith develop novel stimulating, inhibiting or apoptosis-inducing medicaments, for “switching on” or “switching off” of CD4 + CD25 + T cells in vitro and in vivo) and for identifying precursor cells or progeny of the regulatory CD4 + CD25 + T cells.
- methods such as but not restricted to mAb generation, proteomics, DNA chip analysis, subtractive hybridization (in particular (a) identification of “novel”, i.e., hitherto unknown, molecules, or (b) if these molecules are suitable pharmaceutical target structures, to therewith develop novel stimulating, inhibiting or apoptosis-inducing medicaments, for “switching
- the CD4 + CD25 + T cells or expanded CD4 + CD25 + T cells of (1) or (3) above can be used in adoptive transfer therapy, i.e. inject/infuse back into the patients enriched/expanded autologous or non-autologous regulatory T cells to prevent or treat any immune reactions that are too strong and/or pathogenic, i.e.
- autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris or thyreoiditis as well as diseases that have at least some autoimmune aspect in their pathogenesis such as vitiligo, atopic dermatitis, psoriasis vulgaris, etc.
- GVHD graft versus host disease
- graft rejections graft rejections.
- the CD4 + CD25 + T cells or expanded CD4 + CD25 + T cells of (1) or (3) above can be used in conjunction with immature or mature dendritic cells (DC) (or other antigen presenting cells including artificial ones) that are or are not pulsed/loaded/fed with tissue or any other antigen (defined or undefined) in order to activate/stimulate/expand the CD4 + CD25 + T cells in vitro or in vivo, to generate/expand CD24 + CD25 + T cells with a particular desired antigen-specific TCR (T cell receptor).
- DC immature or mature dendritic cells
- T cell receptor antigen-specific TCR
- defined antigens are autoantigens (e.g.
- desmoglein 3 in the case of pemphigus vulgaris, melanA or tyrosinase in case of vitiligo; thyreoglobulin in case of thyreoiditis) or foreign antigens (e.g. pathogen-derived antigens such as Hepatitis C, etc.) or alloantigens/transplantation antigens.
- foreign antigens e.g. pathogen-derived antigens such as Hepatitis C, etc.
- undefined antigens are tissue or cell-derived antigens (eg in the form of necrotic or apoptotic cells or tissue derived RNA or hybrids between cells of interest and dendritic cells/antigen presenting cells or other forms of delivery of undefined antigens into dendritic cells or other antigen presenting cells) or pathogen-derived antigens.
- tissue or cell-derived antigens eg in the form of necrotic or apoptotic cells or tissue derived RNA or hybrids between cells of interest and dendritic cells/antigen presenting cells or other forms of delivery of undefined antigens into dendritic cells or other antigen presenting cells
- pathogen-derived antigens e.g., autologous or non-autologous CD4 + CD25 + T cells and/or dendritic cells can be used.
- the agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (CD154) entities on the T cells as defined in (14) above can be used to remove and to monitor removal of CD4 + CD25 + T cells in vivo e.g. by anti-CD25 and/or anti-CTL-A4 mAb (unmodified or modified e.g. conjugated to toxins) or by immunoadsorption (blood is flowing through columns and CD4 + CD25 + T cells are removed by solid phase-bound antibodies directed to molecules expressed on the surface of CD4 + CD25 + T cells e.g. anti-CD25) in order to enhance immune responses, e.g. dampen regulation by CD4 + CD25 + T cells in vivo, for example, to enhance tumor immunity.
- anti-CD25 and/or anti-CTL-A4 mAb unmodified or modified e.g. conjugated to toxins
- immunoadsorption blood is flowing through columns and CD4 + CD25 + T cells are removed by solid phase-bound antibodies directed to
- the expanded (i.e. activated) CD4 + CD25 + T cells of (3) above may be fixated.
- Such fixated T cells can be obtained by ex vivo treatment of the (expanded) T cells with a suitable fixation agent including, but not limited to, paraformaldehyde, etc.
- a suitable fixation agent including, but not limited to, paraformaldehyde, etc.
- the fixation is performed by suspending the cells in a 0.5 to 5% (w/w) aqueous paraformaldehyde solution, most preferably in an about 2% (w/w) paraformaldehyde solution, for 15 min to 3 h, most preferably for 1 h, followed by appropriate washing steps.
- the CD4 + CD25 + T cells utilized in the medicament of (5) above in the agents of (9) and (14) above, or the method of (10) above can be autologous or non-autologous regulatory T cells.
- non-antologous regulatory T cells it is preferred that the T cells are fixated as mentioned in (H) above.
- composition of (4) and (13) above, the medicament of (5) above, the agents of (7), (9) and (14) above and the T cells utilized in the methods of (6), (8) and (10) above may contain further ingredients such as pharmaceutically/diagnostically suitable carriers, solvents, diluents and additives known to the person skilled in the art. The concentration of these ingredients are to be adapted for respective purpose by the person skilled in the art.
- Tr1 and Th3 cells mediate bystander suppression—without need for direct cell contact—by the secretion of high levels of IL-10 and TGF- ⁇ , respectively (Groux, H. et al., Nature 389:737-742 (1997); Fukaura, H. et al., J. Clin. Invest. 98:70-77 (1996)).
- the best characterized and apparently most important regulatory T cell population identified so far are the CD4 + CD25 + T cells.
- CD4 + CD25 + T cells in human blood that previously had been considered to represent conventional memory T cells (Kanegane, H. et al., Int. Immunol. 3:1349-1356 (1991); Taka, K. et al., Immunol., 72:15-19 (1990); Jackson, A. L. et al., Clin. Immunol.
- CTLA-4 molecule CD152
- CD4 + CD25 + T cells The most interesting and previously unidentified phenotypical feature was that the CTLA-4 molecule (CD152) was already constitutively expressed (at high levels intracellularly, and at low levels at the surface) by the human CD4 + CD25 + T cells, was further upregulated after stimulation via the TCR and maintained at high surface levels for at least a week thereafter (in sharp contrast to CD4 + CD25 ⁇ T cells that expressed CTLA-4 de novo upon stimulation, and only very transiently as described (Thompson, C. B., Allison, J. P., Immunity, 7:445-450 (1998); Chambers, C. A. et al., Immunol. Rev. 153:27-46 (1996)).
- CTLA-4 by CD4 + CD25 ⁇ already supported their relationship to the murine CD4 + CD25 + regulatory T cells as these cells constitutively express CTLA-4 as a molecule essential for their in vivo suppressive activity (Read, S. et al., J. Exp. Med. 192:295-302 (2000); Salomon, B. et al., Immunity, 12:431-440 (2000)).
- the human CD4 + CD25 + T cells showed almost no proliferation upon stimulation, neither in response to polyclonal activation by plate-bound anti CD3+ anti CD28 nor following (even repetitive) stimulation with the most potent natural immunostimulatory cells, i.e. mature (allogeneic) DC.
- CD4 + CD25 ⁇ T cells a sizeable population ( ⁇ 6%) of CD4 + CD25 ⁇ T cells exists in the peripheral blood of normal human adults that in contrast to previous belief do not represent conventional memory but rather regulatory T cells equivalent to the unique population of CD4 + CD25 ⁇ “professional” suppressor/regulatory T cells that have been studied for years in rodents.
- the identification and characterization of the human CD4 + CD25 + regulatory T cells will now allow for their monitoring in various disease states, and has important implications for understanding and treating autoimmunity, graft rejection, and cancer.
- FIG. 1 CD4 + CD25 + T Cells exhibits distinct phenotypical differences to CD4 + CD25 ⁇ T Cells.
- CD4 + T cells were isolated from PBMC by negative MACS sorting, yielding highly purified untouched CD4 + T cells. These cells were labeled with anti CD25 magnetic beads and sorted.
- CD4 + CD25 + and CD4 + CD25 ⁇ T cells were stained with anti CTLA-4 antibody at 37° C. for 2-h. Staining was performed ex vivo and at different time points after activation with immobilized anti CD3+ soluble anti CD28. One representative result of 4 independent experiments is shown.
- FIG. 2 CD4 + CD25 + T cells are nonproliferative/anergic to both allogeneic and polyclonal stimulation, which is partially reversed by the addition of IL-2 and/or IL-15, but not by neutralizing anti IL-10 antibodies.
- CD4 + CD25 + and CD4 + CD25 ⁇ T cells were isolated from adult blood by MACS sorting as in FIG. 1 . 1 ⁇ 10 5 T cells/96 well were stimulated with different numbers of mature allogeneic DC. Proliferation of T cells (triplicate cultures) was determined by [ 3 H]Tdr incorporation. Results were similar in 6 independent experiments.
- 500 U/ml IL-2, 100 ng/ml IL-15, a mixture of 10 U/ml IL-2+1 ng/ml IL-15 or 10 ⁇ g/ml anti IL-10 were added at the onset of culture.
- [ 3 H]Tdr incorporation was measured after 5 days of culture.
- One of 3 independent experiments is shown.
- the addition of IL-2 and/or IL-15 in the absence of a polyclonal or allogeneic T cell stimulus did not induce significant proliferation in the CD25 + or CD25 ⁇ T cell subset (data not shown).
- FIG. 3 CD4 + CD25 + T Cells if stimulated via the TCR suppress the activation of CD4 + and CD8 + T Cells in a cell contact- and dose-dependent manner.
- A, B MACS sorted total CD4 + (A) and CD8 + (B) T cells (105 T cells/96 well) were added to CD4 + CD25 + T cells at the ratios indicated, and stimulated with allogeneic DC at a DC/CD4 + or CD8 + T cells ratio of 1:20. Proliferation was determined by [ 3 H]Tdr incorporation after 5 days. One of 5 independent experiments is shown.
- CD4 + CD25 + T cells were generated/isolated from the same donor (donor I).
- whole CD4 + T cells and CD4 + CD25 + T cells were isolated from another donor (donor II).
- CD4 + CD25 + T cells from donor I and donor II were then added, respectively. Proliferation was determined by [ 3 H]Tdr incorporation after 5 days of culture. Results representative of 3 independent experiments are shown as mean cpm of triplicate cultures.
- FIG. 4 Different cytokine profiles of CD4 + CD25 + and CD4 + CD25 ⁇ T cells.
- Culture Medium RPMI 1640 (Bio Whittaker) supplemented with 1% heat-inactivated autologous plasma, 20 ⁇ g/ml gentamicin (Merck) and 2 mM glutamine (Bio Whittaker) was used for the generation of dendritic cells (DC), X-VIVO-20 (Bio Whittaker) supplemented with 1% heat-inactivated single donor human serum, 20 ⁇ g/ml gentamicin (Merck) and 2 mM glutamine (Bio Whittaker) for T cell culture.
- Cytokines All cytokines used in this study were recombinant human proteins. Final concentrations were: GM-CSF 1,000 U/ml (LeukomaxTM; Novartis), IL-4 800 U/ml (Sandoz), IL-2 (Proleukin; Chiron Corp.) and IL-15 (PeproTech) were used at the concentrations indicated; for DC maturation we used a cocktail consisting of IL-1 ⁇ 2 ng/ml (Sigma); IL-6 1000 U/ml (Sandoz); TNF- ⁇ 10 ng/ml (Bender, Vienna), and PGE 2 1 ⁇ g/ml (Sigma).
- Antibodies For immunostaining PE- and FITC-conjugated Antibodies (Ab) (all from BD Pharmingen) against CD3, CD4, CD5, CD8, CD14, CD19, CD25, CD28, CD45 RA, CD45 RO, CD56, CD62L, CD80, CD83, CD86, CD95, CD95L, CD122, CD152, CD154, HLA-DR, and respective mouse and rat isotype controls were employed.
- Abs PE- and FITC-conjugated Antibodies (Ab) (all from BD Pharmingen) against CD3, CD4, CD5, CD8, CD14, CD19, CD25, CD28, CD45 RA, CD45 RO, CD56, CD62L, CD80, CD83, CD86, CD95, CD95L, CD122, CD152, CD154, HLA-DR, and respective mouse and rat isotype controls were employed.
- Ab used for intracellular cytokine staining were FITC- and PE-conjugated anti IL-2 (MQ1-17H12), anti IL-4 (8D4-8), anti IL-10 (JES3-19F1) and anti IFN- ⁇ (4S.B3), all from BD Pharmingen. Unconjugated anti IL-10 (JES3-19F1) (Pharmingen) and anti TGF- ⁇ (R&D Systems) were used for neutralization experiments, anti CD3 (UCHT1) and anti CD28 (CD28.2) for polyclonal activation of T cells.
- T cells were stimulated with allogeneic DC or with platebound anti CD3 (10 ⁇ g/ml)+soluble anti CD28 (10 ⁇ g/ml) in X-VIVO-20+1% serum. Cytokine analysis was performed at different time points by analysis of supernatants with commercially available ELISA kits for human IL-2, IL-4, IL-10, IFN- ⁇ and TGF- ⁇ (BD Pharmingen). For analysis of intracellular cytokine production T cells were either stimulated with PMA 20 ng/ml and Ca 2+ ionophore A23187 500 ⁇ g/ml (both from SIGMA) for 6 hours or with platebound anti-CD3 and soluble anti-CD28 Ab for 6 hours.
- Monensin, 2 ⁇ M (SIGMA) was added for the last 4 hours of culture.
- Cells were collected, washed, fixed and saponine permeabilized (Fix/perm solution, BD Pharmingen) and stained with cytokine specific Ab or isotype.
- cytokine mRNA analysis T cells were stimulated with platebound anti CD3 and soluble anti CD28 Ab. Cells were analyzed by RNase Protection assay template sets (BD Pharmingen).
- DC were generated from buffy coats or leukapheresis products (both obtained from the Department of Transfusion medicine from healthy donors after informed consent was given) as described (18,19).
- PBMCs were isolated by Ficoll density gradient centrifugation.
- Monocytes were isolated by plastic adherence and cultured in RPMI Medium, supplemented with IL-4 and GM-CSF.
- a maturation cocktail IL-1, IL-6, PGE 2 and TNF ⁇
- nonadherent cells were harvested and constituted mature DC that were >90% double positive for costimulatory molecules (CD80, CD86) and CD83.
- CD4 + T cells were isolated from PBMC with a negative CD4 + T cell isolation kit (Miltenyi Biotech).
- CD4 + CD25 + T cells were isolated from the pure, untouched CD4 + T cells using CD25 Microbeads (Miltenyi Biotech). Isolation of CD8 + T cells was performed using a negative CD8 + T cell isolation kit (Miltenyi Biotech). Purity was assessed by FACS.
- Proliferation Assays To assess proliferation of different CD4 + subtypes 105 sorted T cells were incubated in X-VIVO-20 with different numbers of DC or different concentrations of platebound anti CD3+ soluble anti CD28 in 96-well plates. For assessment of regulatory properties 10 5 bulk CD4 + T cells were cultured with 5 ⁇ 10 3 (in some experiments also with 1 ⁇ 10 3 ) DC in 96-well plates. Purified CD4 + CD25 + or CD4 + CD25 ⁇ T cells were added at different concentrations. After 4-5 days of culture [3H]Tdr (37 KBq/well) was added for additional 16 h. Proliferation was measured using a liquid scintillation counter.
- Transwell experiments were performed in 24-well plates. 10 6 bulk CD4 + T cells were stimulated with 5 ⁇ 10 3 DC. In addition, 10 6 CD4 + CD25 + or CD4 + CD25 ⁇ T cells were either added directly to the culture or were placed in Transwell chambers (Millicell, 0.4 ⁇ m; Millipore). After 5 days of coculture T cells were transferred to 96-well plates (10 5 cells/well) in triplicates. Proliferation was measured after 16 h pulse with [3H]Tdr using a liquid scintillation counter.
- CD4 + CD25 + T Cells Show a Reduced Proliferative Response to Both Allogeneic and Polyclonal Stimulation
- CD4 + T cells were magnetically sorted for their expression of CD25.
- Mature DC are known as the most powerful antigen presenting cells (Bancherau, J., Steinman, R. M., Nature, 392:245-252 (1998)). Nevertheless, the CD4 + CD25 + T cells exhibited virtually no proliferative response when stimulated in vitro with fully mature allogeneic DC in sharp contrast to the CD4 + CD25 ⁇ T cells ( FIG. 2A , B) or the whole CD4 + population ( FIG. 2B ). Interestingly, the CD4 + population depleted of CD25 + T cells showed a higher proliferation when stimulated with allogeneic DC compared to the whole CD4 + population ( FIG. 2B ).
- CD4 + CD25 + T cells would possibly only proliferate upon repetitive stimulation by mature DC.
- the proliferative response of CD25 ⁇ T cells increased somewhat, whereas the response of CD25 + T cells remained very low ( FIG. 2C ).
- Priming and restimulation by allogeneic mature DC resulted in a 30- to 50-fold expansion of the CD25 ⁇ population after two rounds of restimulation.
- there was no significant increase of the CD25 + population (data not shown).
- a slightly ( ⁇ 10%) decreased absolute number of CD4 + CD25 + T cells was harvested as compared to the initial inoculum after the repetitive stimulation in the apparent absence of significant apoptosis or necrosis (data not shown).
- CD4 + CD25 + T cells The exceedingly low proliferative response of CD4 + CD25 + T cells was also apparent when these cell populations were polyclonally stimulated with platebound anti CD3 + soluble anti CD28 ( FIG. 2D ).
- T cell growth factors IL-2 and IL-15 were added to CD4 + CD25 + and CD4 + CD25 ⁇ T cells that were stimulated either with immobilized anti CD3 + soluble anti CD28 ( FIG. 2D , upper panels) or with mature allogeneic DC ( FIG. 2D , lower panels).
- a series of pilot experiments revealed that IL-2 enhanced the proliferation of CD25 + T cells only at high doses (100-1000 U/ml).
- IL-15 had a similar effect, again only at very high doses of 50-100 ng/ml. When both cytokines were mixed, they had strong synergistic effects and doses of 10 U/ml IL-2 plus 10 ng/ml IL-15 were sufficient to promote the proliferation of CD4 + CD25 + T cells. The addition of IL-2 and/or IL-15 in the absence of a polyclonal or allogeneic T cell stimulus did not induce significant proliferation in the CD25 + or CD25 ⁇ T cell subset (data not shown).
- CD4 + CD25 + T Cells Exhibit Distinct Phenotypical Differences to CD4 + CD25 ⁇ T Cells
- CD25 + CD4 + T cell population the expression of various surface molecules on CD4 + CD25 + , CD4 + CD25 ⁇ was compared with that on stimulated CD4 + CD25 ⁇ T cells ( FIG. 1B ). All three populations showed homogenous expression of CD3 and CD4. No contaminating cells such as monocytes, B cells, CD8 + T cells or NK cells could be observed by FACS analysis (data not shown). Without prior stimulation, i.e. ex vivo the CD25 + population already expressed high levels of intracellular, and low levels of cell surface CTLA-4 (CD152).
- Ex vivo isolated CD4 + CD25 + T cells furthermore constitutively expressed CD122 (IL-2R beta chain), HLA-DR ( ⁇ 50%) and consisted primarily ( ⁇ 80%) of CD45RO cells resembling a memory T cell phenotype.
- the ex vivo isolated CD4 + CD25 ⁇ T cells did not express CTLA-4 (neither intracellularly nor on the surface), CD122, or HLA-DR, and more cells expressed CD45RA rather than CD45RO.
- CD4 + CD25 + T Cells if Stimulated via the TCR Suppress the Activation of CD4 + and CD8 + T Cells in a Cell Contact- and Dose-Dependent Manner
- CD25 + T cells were then mixed with CD4 + CD25 + or CD4 + CD25 ⁇ T cell subpopulations at indicated ratios, and stimulated with allogeneic mature DC ( FIG. 3A ).
- CD4 + CD25 + T cells significantly inhibited the proliferation of whole CD4 + T cells, and at a 1:1 ratio virtually blocked it (cpm then represented the background levels of CD25 + T cell proliferation, see FIG. 2A -D).
- the addition of CD25 ⁇ T cells instead of CD25 + T cells slightly enhanced proliferation (not shown).
- CD4 + CD25 ⁇ rapidly expressed CD25 and CD122, i.e. both chains of the IL-2R, upon polyclonal (see FIG. 1B ) as well stimulation by allogeneic DC (data not shown) this finding indicated that the suppressive activity of the CD4 + CD25 + T cell subset was not simply due to consumption or passive adsorption of IL-2 via their IL-2R.
- CD4 + CD25 + T cells exerted also a suppressive activity on whole CD8 + T cells albeit downregulation was less intense ( FIG. 3B ).
- FIG. 3D Transwell chamber experiments were performed to investigate, whether the regulatory function of the CD4 + CD25 + T cells was mediated primarily by soluble factors or required cell-cell contact.
- the CD4 + CD25 + T cells suppress proliferation of whole CD4 + T cells almost completely in the presence of allogeneic DC. Separation of the two populations in Transwell chambers virtually abolished their suppressive effect.
- These observations suggested that direct cell contact is essential for the inhibitory capacity of CD4 + CD25 + T cells, as the semipermeable membrane of Transwell chambers allows free passage of soluble factors, but excludes direct cell contact.
- the Transwell experiments also confirmed that consumption of IL-2 by CD4 + CD25 + T cells was not the mechanism responsible for suppression.
- CD4 + CD25 + T Cells Predominantly Secrete IL-10
- CD4 + CD25 + and CD4 + CD25 ⁇ T cells were activated with plate-bound anti CD3+ anti CD28. Supernatants were then analyzed by ELISA, and RNA expression was studied by RNase protection assays. In addition, intracellular cytokine staining was performed to determine the percentage of cells releasing a certain cytokine. As shown in FIG. 4 CD4 + CD25 ⁇ T cells predominantly secreted IFN- ⁇ and IL-2, with little secretion of IL-10 and IL-4, resembling a Th1 like profile.
- CD4 + CD25 + T cells on the other hand predominantly produced IL-10 and only low levels of IL-2, IL-4 and IFN- ⁇ , resembling Tr1 cells. Comparison of both subpopulations at the RNA level revealed, that CD25 + T cells express more IL-10, less IFN- ⁇ and similar levels of IL-2 mRNA compared to CD25 ⁇ T cells.
- IL-1 receptor antagonist (IL-1 Ra) mRNA was found predominantly in CD4 + CD25 + T cells, while significant IL-1, mRNA levels were only present in CD4 + CD25 ⁇ T cells. TGF- ⁇ was expressed at similarly low levels in both cell types.
- CD4 + CD25 ⁇ and CD4 + CD25 + T cells were isolated from whole CD4 + T cells from adult blood by MACS® sorting as described.
- CD4 + CD25 + T cells were divided into three parts. One fraction was activated with 10 ⁇ g/ml platebound anti-CD3 and 10 ⁇ g/ml soluble anti-CD28 antibodies overnight. Next day this fraction and one part of the non activated CD4 + CD25 + T cells were fixed with 2% formaldehyde for 1 hour. The third part was left untreated. Cells were washed three times.
Abstract
The present invention provides suppressive and/or regulative human CD4+CD25+ T cells, a method for expanding same, and the use of the suppressive and/or regulative human CD4+CD25+ T cells and the expanded T cells as regulatory agent.
Description
- The present invention provides suppressive and/or regulative human CD4+CD25+ T cells, a method for expanding same, and the use of the suppressive and/or regulative human CD4+CD25+ T cells and of the corresponding expanded T cells as regulatory agent.
- Immunological self-tolerance is critical for the prevention of autoimmunity and maintenance of immune homeostasis. The ability of the immune system to discriminate between self and non-self is controlled by mechanisms of central and peripheral tolerance. Central tolerance involves deletion of self-reactive T lymphocytes in the thymus at an early stage of development (Rocha, B. and von Boehmer, H., Science 251:1225-1228 (1991); Kisielow, P. et al., Nature 333:742-746 (1988)). Several mechanisms of peripheral tolerance have been described, including T cell anergy and ignorance (Rocha, B. and von Boehmer, H., Science 251:1225-1228 (1991); Kisielow, P. et al., Nature, 333:742-746 (1988); Schwartz, R. H., Science 248:1349-1356 (1990); Miller, J. F. A. P. and Heath, W. R., Immunol. Rev. 133:131-150 (1993)). Studies ongoing for more than a decade in rodents have provided firm evidence for the existence of a unique CD4+CD25+ population of “professional” regulatory/suppressor T cells that actively and dominantly prevent both the activation as well as the effector function of autoreactive T cells that have escaped other mechanisms of tolerance (Sakaguchi, S. et al., J. Immunol. 155:1151-1164 (1995); Takahashi, T. et al., Int. Immunol. 10:1969-1980 (1998); Itoh, M. et al., J. Immunol. 162:5317-5326 (1999)). The elimination or inactivation of these cells resulted in severe autoimmune disease, and was also found to enhance immune responses to alloantigens and even tumors (Sakaguchi, S. et al., J. Immunol. 155:1151-1164 (1995); Itoh, M. et al., J. Immunol. 162:5317-5326 (1999); Shimizu, J. et al., J. Immunol. 163:5211-5218 (1999)). Recent studies revealed that the CD4+CD25+ regulatory T cells constitute a rather homogenous population (Thornton, A. M., Shevach, E. M., J. Immunol. 164:183-190 (2000)), are derived from the thymus (Itoh, M. et al., J. Immunol. 162:5317-5326 (1999)), are naturally non-proliferative (i.e. anergic) to stimulation via the TCR, but require activation via their TCR to become suppressive and to inhibit the proliferation of CD4+ or CD8+ T cells. Once activated, however, their regulatory/suppressor function was completely antigen-nonspecific, cytokine-independent yet cell contact dependent (Thornton, A. M., Shevach, E. M., J. Immunol. 164:183-190 (2000)). The exact mechanisms of suppression, notably the cell surface and/or short-range soluble molecules involved in the T-T interaction, have yet to be characterized. New in vitro data suggest that the CD4+CD25+ T cells inhibit the proliferation of responders by inhibiting their IL-2 production (Thornton, A. M., Shevach, E. M., J. Exp. Med. 188:287-296 (1998)). Recent in vivo studies suggest that the function of CD4+CD25+ T cells is crucially dependent on signaling via the CTLA-4/CD152 molecule which was found to be constitutively expressed on CD4+CD25+ T cells (Read, S. et al., J. Exp. Med. 192:295-302 (2000); Salomon, B. et al., Immunity 12:431-440 (2000); Takahashi, T. T. et al., J. Exp. Med. 192:303-310 (2000)).
- Although it has been evident for years that in rodents the CD4+CD25+ T cell population constitutes a unique lineage of “professional” regulatory/suppressor T cells which are crucial for the prevention of spontaneous autoimmune disease (Sakaguchi, S. et al., J. Immunol. 155:1151-1164 (1995)), it is unknown to date, whether CD4+4T cells exhibiting similar functional properties are naturally occurring in man. The removal and/or functional impairment of these cells in vivo in mice e.g. by anti-CD25 and/or anti-CTLA-A4 mAb treatment of animals induces various spontaneous autoimmune diseases AND rejection of tumors. The mechanism is that removal/impairment of these cells removes their negative control of autoreactive T cells so that these T cells become active. If one gives back the CD4+CD25+ T cells by adoptive transfer into these animals regluation is restored and autoimmunity/tumor rejection is stopped.
- As set forth above, it is totally unknown to date whether CD4+ T cells exhibiting similar functional properties are naturally present in man. The preparation of human T cells with regulatory properties, which are, however, no CD4+CD25+ T cells is known in the art. E. g. Jonuleit, H. et al., J. Exp. Med 192:1213-1222 (2000) describe the induction of regulatory T cells from human naïve T cells by repetitive stimulation with immature dendritic cells. Most of this work was done with T cells from cord blood which is the richest source of truly naïve T cells. It is to be noted that CD4 CD25+ T cells are constitutively detectable in the human blood from early time points on. The subject of Jonuleit et al. is not a naturally occurring population. De Jong, P. et al., Int. Immunol. 6:631-638 (1994) describe the effect of TGF-β1 on naïve and memory CD4+ T cells. A differential effect is shown, with stimulatory effect on primarily activated CD45 RA+ CD4+ T cells. Proliferation of CD45 RO+ CD4+ T cells or secondary stimulated CD45 RO+ cells is suppressed. In the case of CD45 RA+T cells TGF-β leads to an increased mean of fluorescens of CD25. The effects described here solely relate to proliferation of T cells. A regulatory capacity of naïve TGF-β treated T cells is not shown.
- Surprisingly it was now found that CD4+CD25+, primarly CD45RO+ T cells (mean 6% of CD4+ T cells), hereinafter shortly referred to as “CD4+CD25+ T cells”, are present in human blood, in particular the peripheral blood of adult healthy volunteers. In the past T cells exhibiting the phenotype (i.e., suppressive/regulatory CD4+CD25+ T cells) have been known for years but they were misinterpreted to be conventional memory cells (Kanegane, H. et al., Int. Immunol., 3:1349-1356 (1991); Taka, K. et al., Immunol. 72:15-19 (1990); Jackson, A. L. et al., Clin. Immunol. Innunopathol. 54:126-133 (1990)). In contrast to previous reports the human CD4+CD25+ T cells are not conventional memory cells but rather regulatory cells exhibiting functional properties identical to their rodent counterparts. CTLA-4 (CD152), for example, which is essential for the in vivo suppressive activity of CD4+CD25+ T cells, was constitutively expressed, and remained strongly upregulated after stimulation. The cells were non-proliferative to stimulation via their TCR, but the anergic state was partially reversed by IL-2 and IL-15. Upon stimulation with allogeneic (but not syngeneic) mature dendritic cells or plate-bound anti CD3+ anti-CD28 the CD4+CD25+ T cells released IL-10, and in coculture experiments suppressed the activation and proliferation of CD4+ and CD8+ T cells. Suppression proved IL-10 independent, yet contact dependent as in the mouse. The identification of regulatory CD4+CD25+ T cells has important implications for the study of tolerance in man, notably in the context of autoimmunity, transplantation, and cancer.
- The present invention provides
- (1) suppressive and/or regulative human CD4+CD25+ T cells;
- (2) a method for expanding CD4+CD25+ T cells as defined in (1) above, which method comprises stimulating the cells with a T cell stimulating agent or with antigen-presenting cells ex vivo and in vivo;
- (3) expanded human CD4+ CD25+ T cells obtainable by the method as defined in (2) above, preferably by the ex vivo method defined in (2) above;
- (4) a pharmaceutical composition comprising the human CD4+ CD25+ T cells as defined in (1) or (3) above;
- (5) use of CD4+ CD25+ T cells as defined in (1) or (3) above for preparing a regulatory medicament;
- (6) a method to identify, monitor and/or remove CD4+CD25+ T cells from human blood and other tissues ex vivo or in vivo, which method comprises
- (i) utilizing agents/ligands specifically binding to the CD4, and/or CD25, and/or CTL-A4 (CD154) entities on the T cells, preferably anti-CD4 and/or anti-CD25, and/or anti-CTL-A4 antibodies, and/or
- (ii) utilizing immunoadsorption methods; and/or
- (iii) utilizing a stimulating agent or antigen presenting cells as defined in (2) above;
- (7) use of a T cell stimulating agent or antigen presenting cells as defined in (2) above for preparing an agent to induce regulatory CD4+CD25+ T cells in vivo, preferably for preparing an agent for treating autoimmune diseases in a patient;
- (8) use of CD4+CD25+ T cells as defined in (1) or (3) above
- (a) in assays that will allow to identify other growth and/or functionally modifying (inhibitory/enhancing)/apoptotic or anti-apoptotic factors
- (b) for identifying molecules expressed by the CD4+CD25+ T cells including identification of novel molecules on said cells, or if presenting molecules which are deemed pharmaceutically active, or
- (c) for identifying precursor cells or progeny of the regulatory CD4+CD25+ T cells;
- (9) use of the enriched CD4+CD25+ T cells of (1) above or the expanded T cells of (3) above for preparing an agent for adoptive transfer therapy, an agent for treating diseases with enhanced immunity including but not limited to autoimmune diseases, or an agent for preventing/treating transplantation reactions such as graft versus host disease and graft rejections;
- (10) method for adoptive transfer therapy which comprises injecting/infusing back into the patients enriched/expanded autologous or non-autologous regulatory CD4+CD25+ T cells as defined in (1) or (3) above to prevent or treat any immune reactions that are too strong and/or pathogenic, or to prevent/treat transplantation reactions such as graft versus host disease and graft rejections;
- (11) a method for preparing CD4+CD25+ T cells with a particular desired antigen-specific T cell receptor which comprises (i) activating/stimulating/expanding the CD4+CD25+ T cells according to (1) above with antigen presenting cells, preferably immature or mature dendritic cells (DC), presenting said antigen in vitro or in vivo; or
- (ii) utilizing a ligand/antibody to a particular T cell receptor expressed on (subsets of) CD4+CD25+ regulatory T cells, or a MHC-peptide complex binding to a particular T cell receptor on (subsets of) CD4+CD25+ T cells;
- (12) CD4+CD25+ T cells obtainable by the method as defined in (11) above, or by transfection of a T cell receptor of desired antigen specificity into ex vivo isolated or expanded T cells;
- (13) pharmaceutical composition comprising the T cells of (12) above, preferably said pharmaceutical composition being suitable to treat diseases with enhanced immunity including, but not limited to, autoimmune diseases, graft versus host disease and graft rejections; and
- (14) use of agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (CD154) entities on the T cells, including but not limited to ligands/antibodies, such as anti-CD25 and/or anti-CTL-A4 mAb, or antibodies or MHC-peptide complexes or other ligands binding to T cell receptors on (subsets of) CD4+CD25+ T cells for preparing a medicament for removal or functional impairment of CD4+CD25+ T cells in vivo in order to enhance immune responses, including dampen regulation by CD4+CD25+ T cells in vivo, for example, to enhance tumor immunity.
-
FIG. 1 shows that CD4+CD25+ T cells exhibit distinct phenotypical differences as compared to CD4+CD25− T cells. -
FIG. 2 shows that CD4+CD25+ T cells are nonproliferative/anergic to both allogeneic and polyclonal stimulation, which is partially reversed by the addition of IL-2 and/or IL-15, but not by neutralizing anti IL-10 antibodies. -
FIG. 3 shows that CD4+CD25+ T cells, if stimulated via the TCR, suppress the activation of CD4+ and CD8+ T cells in a cell contact- and dose-dependent manner. -
FIG. 4 shows that the cytokine profiles of CD4+CD25+ and CD4+CD25− T cells are different. -
FIG. 5 shows that activated and fixated CD4+CD25+ cells still exhibit regulatory capacity. - The embodiments (1) to (14) of the invention are hereinafter described in more detail:
- (A) The phenotypical characterization of the human CD4+CD25+ T cells now allows the identification, monitoring (e.g. by FACS), isolation and removal of these cells from human blood and other tissues ex vivo (hereinafter occasionally referred to as “in vitro”) or in vivo. This isolation or removal can be achieved by contacting the human blood or other tissues with suitable agents ex vivo. Suitable agents are in particular anti-CD4, anti-CD25, anti-CTL-A4 (CD154) antibodies, etc.
- (B) The CD4+CD25+ T cells can be expanded ex vivo by stimulation of the cells by treatment with suitable T cell stimulating agents or with antigen presenting cells (hereinafter shortly referred to as “APCs”). Suitable T cell stimulating agents suitable for the methods of (2) and (6) above include, but are not limited to, compositions comprising
- (a) anti-CD3 and/or anti-CD28 ligands/monoclonal antibodies (mAb) including superagonistic antibodies; (b) a ligand/antibody to T cell receptors on the surface of CD4+CD25+ T cells or to T cell receptor components; or
- (c) MHC-peptide complexes binding to the T cell receptors expressed on the surface of regulatory T cells; or
- (d) PMA (as well as other phorbolester)+ionomycin (or other calcium ionophores).
- “Ligand” or “ligands” in accordance with the present invention relates to all kinds of compounds capable of binding to specific molecules (including polynucleotides and polypeptides such as cell receptors, CD25, CTL-A4, etc.). A preferred ligand is a monoclonal antibody or a fragment thereof. The terms “ligand” and “antibody” are used interchangeable throughout the application text.
- Suitable APCs include autologous or non-autologous or artificial antigen-presenting cells (e.g. dendritic cells (for the preparation of dendritic cells see e.g. WO 93/20185, WO 97/29182 and EP-A-0 922 758), etc.). Said T cell stimulating agents and antigen-presenting cells can be used together with IL-2 or IL-15 or a combination thereof. Instead of IL-2/IL-15, other cytokines that use the gamma chain common to several cytokine receptors can also be used (including, but not restricted to, IL-7 and IL-9). Furthermore, IFN alpha and IL-10, which are known to promote the generation of other regulatory cells (Groux, H. et al., Nature 389:737-742 (1997); Roncarolo, M. G., J. Exp. Med. 193:F5-F9 (2001)) also promote the generation/expansion of these cells. Finally, other methods for polyclonal or oligoclonal (e.g. by superantigens) T cell stimulation are also applicable (anti-CD3 and/or anti-CD28 lingands/antigens including superagonistic antibodies; PMA+ ionomycin; etc.). These stimulating agents or antigen presenting cells may be used for the expansion in amounts well-known for a person skilled in the art.
- (C) The identification of the CD4+CD25+ T cells also allows to monitor and expand CD4+CD25+ T cells in vivo (e.g. by adminstering the T cells stimulating agents defined above, such as IL-2+IL-15 or IL-10+IFNα to patients, with or without the dendritic cells/antigen presenting cells) to induce regulatory T cells e.g. to fight autoimmune diseases.
- (D) The CD4+CD25+ T cells or expanded CD4+CD25+ T cells of (1) or (3) above can be used in assays that will allow to identify other growth and/or functionally modifying (inhibitory/enhancing)/(apoptotic or anti-apoptotic) factors that can be used in vitro or in vivo (e.g. to stimulate or to remove or functionally disturb the CD4+CD25+ T cells). These T cells are also suitable for identifying molecules expressed by the CD4+CD25+ T cells by methods such as but not restricted to mAb generation, proteomics, DNA chip analysis, subtractive hybridization (in particular (a) identification of “novel”, i.e., hitherto unknown, molecules, or (b) if these molecules are suitable pharmaceutical target structures, to therewith develop novel stimulating, inhibiting or apoptosis-inducing medicaments, for “switching on” or “switching off” of CD4+CD25+ T cells in vitro and in vivo) and for identifying precursor cells or progeny of the regulatory CD4+CD25+ T cells.
- (E) The CD4+CD25+ T cells or expanded CD4+CD25+ T cells of (1) or (3) above can be used in adoptive transfer therapy, i.e. inject/infuse back into the patients enriched/expanded autologous or non-autologous regulatory T cells to prevent or treat any immune reactions that are too strong and/or pathogenic, i.e. to treat autoimmunity in its broadest sense (including but not limited to classical autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris or thyreoiditis as well as diseases that have at least some autoimmune aspect in their pathogenesis such as vitiligo, atopic dermatitis, psoriasis vulgaris, etc.). Also to prevent/treat transplantation reactions such as GVHD (graft versus host disease) and graft rejections.
- (F) The CD4+CD25+ T cells or expanded CD4+CD25+ T cells of (1) or (3) above (as well as the expansion method defined in (2) above, the pharmaceutical composition of (4) above and the use of (5) and (7) to (9) above can be used in conjunction with immature or mature dendritic cells (DC) (or other antigen presenting cells including artificial ones) that are or are not pulsed/loaded/fed with tissue or any other antigen (defined or undefined) in order to activate/stimulate/expand the CD4+CD25+ T cells in vitro or in vivo, to generate/expand CD24+CD25+ T cells with a particular desired antigen-specific TCR (T cell receptor). Examples of defined antigens are autoantigens (e.g. desmoglein 3 in the case of pemphigus vulgaris, melanA or tyrosinase in case of vitiligo; thyreoglobulin in case of thyreoiditis) or foreign antigens (e.g. pathogen-derived antigens such as Hepatitis C, etc.) or alloantigens/transplantation antigens. Examples of undefined antigens are tissue or cell-derived antigens (eg in the form of necrotic or apoptotic cells or tissue derived RNA or hybrids between cells of interest and dendritic cells/antigen presenting cells or other forms of delivery of undefined antigens into dendritic cells or other antigen presenting cells) or pathogen-derived antigens. Autologous or non-autologous CD4+CD25+ T cells and/or dendritic cells can be used.
- (G) The agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (CD154) entities on the T cells as defined in (14) above can be used to remove and to monitor removal of CD4+CD25+ T cells in vivo e.g. by anti-CD25 and/or anti-CTL-A4 mAb (unmodified or modified e.g. conjugated to toxins) or by immunoadsorption (blood is flowing through columns and CD4+CD25+ T cells are removed by solid phase-bound antibodies directed to molecules expressed on the surface of CD4+CD25+ T cells e.g. anti-CD25) in order to enhance immune responses, e.g. dampen regulation by CD4+CD25+ T cells in vivo, for example, to enhance tumor immunity.
- (H) In another preferred embodiment of the invention the expanded (i.e. activated) CD4+CD25+ T cells of (3) above (and also the T cells of (1) and (12) above) may be fixated. Such fixated T cells can be obtained by ex vivo treatment of the (expanded) T cells with a suitable fixation agent including, but not limited to, paraformaldehyde, etc. Preferably the fixation is performed by suspending the cells in a 0.5 to 5% (w/w) aqueous paraformaldehyde solution, most preferably in an about 2% (w/w) paraformaldehyde solution, for 15 min to 3 h, most preferably for 1 h, followed by appropriate washing steps.
- (I) The CD4+CD25+ T cells utilized in the medicament of (5) above in the agents of (9) and (14) above, or the method of (10) above can be autologous or non-autologous regulatory T cells. In case of non-antologous regulatory T cells it is preferred that the T cells are fixated as mentioned in (H) above.
- (J) The pharmaceutical composition of (4) and (13) above, the medicament of (5) above, the agents of (7), (9) and (14) above and the T cells utilized in the methods of (6), (8) and (10) above may contain further ingredients such as pharmaceutically/diagnostically suitable carriers, solvents, diluents and additives known to the person skilled in the art. The concentration of these ingredients are to be adapted for respective purpose by the person skilled in the art.
- The concept of suppressor or immunoregulatory T cells has been revitalized during the past few years by the better delineation of several regulatory cell types in rodents, the mutual relationship of which is not yet finally defined. The so-called Tr1 and Th3 cells mediate bystander suppression—without need for direct cell contact—by the secretion of high levels of IL-10 and TGF-β, respectively (Groux, H. et al., Nature 389:737-742 (1997); Fukaura, H. et al., J. Clin. Invest. 98:70-77 (1996)). The best characterized and apparently most important regulatory T cell population identified so far are the CD4+CD25+ T cells. They occur naturally in rodents (representing about 10% of CD4+ cells in lymphoid organs), are characterized by constitutive expression of CD25 (IL-2R-alpha), and are clearly of crucial importance for maintaining tolerance and preventing autoimmune disease in vivo. Surprisingly, a cell population exhibiting equivalent properties has not been described in humans to date. Here we have demonstrated, that the CD4+CD25+ T cells in human blood that previously had been considered to represent conventional memory T cells (Kanegane, H. et al., Int. Immunol. 3:1349-1356 (1991); Taka, K. et al., Immunol., 72:15-19 (1990); Jackson, A. L. et al., Clin. Immunol. Innunopathol. 54:126-133 (1990)) in fact appear to be the exact human counterpart of the unique CD4+CD25+ regulatory T cells that have been known and studied for many years in rodents. We were able to isolate the CD4+CD25+ T cells from adult blood in sizeable quantities (average 6% of CD4+ T cells) so that a detailed study and comparison to CD4+CD25− T cells could be undertaken. It turned out that the human cells share the key phenotypical and functional features with the murine CD4+CD25+ immunoregulatory T cells. The most interesting and previously unidentified phenotypical feature was that the CTLA-4 molecule (CD152) was already constitutively expressed (at high levels intracellularly, and at low levels at the surface) by the human CD4+CD25+ T cells, was further upregulated after stimulation via the TCR and maintained at high surface levels for at least a week thereafter (in sharp contrast to CD4+CD25− T cells that expressed CTLA-4 de novo upon stimulation, and only very transiently as described (Thompson, C. B., Allison, J. P., Immunity, 7:445-450 (1998); Chambers, C. A. et al., Immunol. Rev. 153:27-46 (1996)). The expression pattern of CTLA-4 by CD4+CD25− already supported their relationship to the murine CD4+CD25+ regulatory T cells as these cells constitutively express CTLA-4 as a molecule essential for their in vivo suppressive activity (Read, S. et al., J. Exp. Med. 192:295-302 (2000); Salomon, B. et al., Immunity, 12:431-440 (2000)). Like their murine counterparts the human CD4+CD25+ T cells showed almost no proliferation upon stimulation, neither in response to polyclonal activation by plate-bound anti CD3+ anti CD28 nor following (even repetitive) stimulation with the most potent natural immunostimulatory cells, i.e. mature (allogeneic) DC. When these stimuli were combined with high doses of IL-2 (500 U/ml) anergy was partially reversed as described in the mouse (Thornton, A. M., Shevach, E. M., J. Immunol., 164:183-190 (2000)). A novel finding was that IL-15 at high doses (50-100 ng/ml) induced comparable proliferation, and that the combined action of IL-2 and IL-15 even at lower doses (10 U/ml and 10 ng/ml, respectively) had a strong synergistic action and induced vigorous proliferation. This might proof important, as expansion of CD4+CD25+ T cells is vital for potential therapeutic applications and cloning of these cells for further more detailed studies (including mechanistic and molecular ones). Of interest was that neutralizing anti IL-10 mAb failed to promote proliferation indicating that the release of IL-10 by these cells was not causing anergy in an autocrine fashion. In coculture experiments the CD4+CD25+ T cells displayed another key feature in that they suppressed yet only upon activation via their own TCR the proliferation of CD25−CD4+ or CD8+ T cells in a contact- and dose-dependent, yet cytokine-independent manner. Our ex vivo system has not allowed us to investigate whether the suppression is completely antigen-nonspecific as has recently been shown in the mouse by taking advantage of TCR transgenic mice (Thornton, A. M., Shevach, E. M., J. Immunol., 164:183-190 (2000)). Respective mechanistic studies might be possible, however, by employing our IL-2+IL-15 approach for the expansion of these cells.
- It is most remarkable that a recent report has shown that T cells with regulatory properties and a phenotype virtually identical to the CD4+CD25+ T cells we have isolated ex vivo from human blood can be generated in vitro by repetitive stimulation of human naive T cells with immature DC (Jonuleit, H. et al., J. Exp. Med., 192:1213-1222 (2000)). In the mouse CD4+CD25+ regulatory T cell populations are continuously generated in the thymus (Itoh, M. et al., J. Immunol. 162:5317-5326 (1999)), yet the maintenance of regulatory T cells in the periphery requires the presence of tissue-specific antigens and IL-2 (25, 26). Based on the two supplementary findings (Jonuleit, H. et al., J. Exp. Med., 192:1213-1222 (2000)) it is certainly tempting to speculate, that immature DC that have sampled peripheral tissues via the uptake of apoptotic antibodies (Steinman, R. M. et al., J. Exp. Med., 191:411-416 (2000); Roncarolo, M. G. et al., J. Exp. Med. 193:F5-F9 (2001)), and present universal or tissue-specific autoantigens, are responsible for the survival and possibly slight proliferation of thymic regulatory T cell emigrants. It is believed that the survival of the ex vivo isolated CD4+CD25+ regulatory T cells can be promoted by interaction with immature DC, and that the recently reported “generation” of CD4+CD25+ T cells from naïve T cells by immature DC in vitro (Jonuleit, H. et al., J. Exp. Med., 192:1213-1222 (2000)) possibly rather represents maintenance of survival of preexisting CD4+CD25+ in the initial inoculum. It is also of note that it was found that interaction of ex vivo isolated human CD4+CD25+ T cells with syngeneic mature DC was insufficient to activate their suppressive properties while allogeneic mature DC were potent inducers of regulation. This observation again suggests testable hypotheses. For example, will immature in contrast to mature syngeneic DC activate CD4+CD25+ T cells (suggesting that they carry some specific ligand for interaction), or will they do so only after ingestion of apoptotic bodies (suggesting that presentation of autoantigens is required)? Furthermore, can mature DC that present nominal recall antigens (e.g. influenza proteins/peptides) stimulate T cells both in the CD4+CD25− T cell population and the CD4+CD25+ T suggesting that besides autoantigens also the recognition of foreign antigens could trigger regulation at inflammatory sites.
- In summary, it was shown that a sizeable population (˜6%) of CD4+CD25− T cells exists in the peripheral blood of normal human adults that in contrast to previous belief do not represent conventional memory but rather regulatory T cells equivalent to the unique population of CD4+CD25− “professional” suppressor/regulatory T cells that have been studied for years in rodents. The identification and characterization of the human CD4+CD25+ regulatory T cells will now allow for their monitoring in various disease states, and has important implications for understanding and treating autoimmunity, graft rejection, and cancer.
- The invention is further explained by the following figures and examples which, however, are not intended to limit the invention:
- Figures
-
FIG. 1 : CD4+CD25+ T Cells exhibits distinct phenotypical differences to CD4+CD25− T Cells. CD4+ T cells were isolated from PBMC by negative MACS sorting, yielding highly purified untouched CD4+ T cells. These cells were labeled with anti CD25 magnetic beads and sorted. - (A): Sorting resulted in virtually pure CD25+ T cells. A representative result out of 20 independent standardized experiments is shown.
- (B): The phenotype of CD4+CD25+, CD4+CD25− and activated CD4+CD25− T cells was analyzed as described in Materials & Methods. In addition, CD4+CD25− T cells were activated with immobilized anti CD3+ soluble anti CD28. After activation cells were labeled with anti CD25 magnetic beads and sorted. Results were similar in 5 independent experiments.
- (C): CD4+CD25+ and CD4+CD25− T cells were stained with anti CTLA-4 antibody at 37° C. for 2-h. Staining was performed ex vivo and at different time points after activation with immobilized anti CD3+ soluble anti CD28. One representative result of 4 independent experiments is shown.
-
FIG. 2 : CD4+CD25+ T cells are nonproliferative/anergic to both allogeneic and polyclonal stimulation, which is partially reversed by the addition of IL-2 and/or IL-15, but not by neutralizing anti IL-10 antibodies. - (A) CD4+CD25+ and CD4+CD25− T cells were isolated from adult blood by MACS sorting as in
FIG. 1 . 1×105 T cells/96 well were stimulated with different numbers of mature allogeneic DC. Proliferation of T cells (triplicate cultures) was determined by [3H]Tdr incorporation. Results were similar in 6 independent experiments. - (B): Whole CD4+, CD4+CD25+ and CD4+CD25− T cells were treated as described in (A). Proliferation in triplicate cultures was determined by [3H]Tdr incorporation (representative result of 5 independent experiments).
- (C): MACS sorted CD4+CD25+ and CD4+CD25− T cells were primed and restimulated every week with mature allogeneic DC from the same donor (DC:T cell ratio of 1:20). Proliferation (1×105 T cells/96 well) was determined by [3H]Tdr incorporation. Similar results were obtained in 3 independent experiments.
- (D): CD4+CD25+ and CD4+CD25− T cells were stimulated with immobilized anti CD3 (10 μg/ml) and soluble anti CD28 (10 μg/ml) [upper panels] or with mature allogeneic DC [lower panels] as described in (A). 500 U/ml IL-2, 100 ng/ml IL-15, a mixture of 10 U/ml IL-2+1 ng/ml IL-15 or 10 μg/ml anti IL-10 were added at the onset of culture. [3H]Tdr incorporation was measured after 5 days of culture. One of 3 independent experiments is shown. The addition of IL-2 and/or IL-15 in the absence of a polyclonal or allogeneic T cell stimulus did not induce significant proliferation in the CD25+ or CD25− T cell subset (data not shown).
-
FIG. 3 : CD4+CD25+ T Cells if stimulated via the TCR suppress the activation of CD4+ and CD8+ T Cells in a cell contact- and dose-dependent manner. - (A, B): MACS sorted total CD4+ (A) and CD8+ (B) T cells (105 T cells/96 well) were added to CD4+CD25+ T cells at the ratios indicated, and stimulated with allogeneic DC at a DC/CD4+ or CD8+ T cells ratio of 1:20. Proliferation was determined by [3H]Tdr incorporation after 5 days. One of 5 independent experiments is shown.
- (C): DC and CD4+CD25+ T cells were generated/isolated from the same donor (donor I). In addition, whole CD4+ T cells and CD4+CD25+ T cells were isolated from another donor (donor II). 105 whole CD4+ T cells/96 well were cultured with 5×103 DC/well (i.e. DC:T ratio=1:20; results were comparable at a DC:T ratio of 1:100, not shown). CD4+CD25+ T cells from donor I and donor II were then added, respectively. Proliferation was determined by [3H]Tdr incorporation after 5 days of culture. Results representative of 3 independent experiments are shown as mean cpm of triplicate cultures.
- (D): Whole CD4+ T cells or CD4+CD25+ T cells were (105 T cells/96 well) stimulated with 5×103 allogeneic mature DC (DC:T ratio=1:20) (upper 2 panels). In addition, whole CD4+ T cells were cocultured with CD4+CD25+ T cells at a ratio of 1:1 (105 T cells/96 well each) and stimulated with allogeneic DC again at a DC:T ratio of 1:20 in the presence or absence of 10 μg/ml anti IL-10, 2 μg/ml TGF-beta, 500 U/ml IL-2, 50 ng/ml IL-15 or a mixture of 10 U/ml IL-2, 1 ng/ml IL-15. In a parallel Transwell approach the CD4+CD25+ T cells were stimulated with allogeneic DC (DC/ T cell ratio of 1:20) in a Transwell chamber, and whole CD4+ T cell responders were put into the well together with allogeneic DC again at a DC:T ratio of 1:20. Proliferation after 5 days of culture was determined by [3H]Tdr incorporation. One of four representative experiments is shown.
-
FIG. 4 : Different cytokine profiles of CD4+CD25+ and CD4+CD25− T cells. - (A) MACS sorted CD4+CD25+ and CD4+CD25− T cells were stimulated with PMA (20 ng/ml) and A23187 Ca2+ ionophore (500 μg/ml) for 6 h. Monensin (2 μM) was added for the last 5 h. Staining of CD3 surface expression was performed. Cells were washed, fixed, permeabilised and stained for detection of intracellular cytokines using FITC- or PE-conjugated specific antibodies. One of 5 independent experiments with similar results is shown. Results were identical when T cells were stimulated with platebound anti-CD3+ soluble anti-CD28 AB (not shown).
- (B): CD4+CD25+ and CD4+CD25− T cells were activated with platebound anti CD3+ soluble anti CD28. After 48 h of culture analysis of RNA expression was performed by RNase Protection assay.
- (C): Cytokines in the supernatant were measured by ELISA (one of 5 independent experiments is shown).
- Material and Methods
- Culture Medium: RPMI 1640 (Bio Whittaker) supplemented with 1% heat-inactivated autologous plasma, 20 μg/ml gentamicin (Merck) and 2 mM glutamine (Bio Whittaker) was used for the generation of dendritic cells (DC), X-VIVO-20 (Bio Whittaker) supplemented with 1% heat-inactivated single donor human serum, 20 μg/ml gentamicin (Merck) and 2 mM glutamine (Bio Whittaker) for T cell culture.
- Cytokines: All cytokines used in this study were recombinant human proteins. Final concentrations were: GM-CSF 1,000 U/ml (Leukomax™; Novartis), IL-4 800 U/ml (Sandoz), IL-2 (Proleukin; Chiron Corp.) and IL-15 (PeproTech) were used at the concentrations indicated; for DC maturation we used a cocktail consisting of IL-
1β 2 ng/ml (Sigma); IL-6 1000 U/ml (Sandoz); TNF-α 10 ng/ml (Bender, Vienna), andPGE 2 1 μg/ml (Sigma). - Antibodies: For immunostaining PE- and FITC-conjugated Antibodies (Ab) (all from BD Pharmingen) against CD3, CD4, CD5, CD8, CD14, CD19, CD25, CD28, CD45 RA, CD45 RO, CD56, CD62L, CD80, CD83, CD86, CD95, CD95L, CD122, CD152, CD154, HLA-DR, and respective mouse and rat isotype controls were employed. Ab used for intracellular cytokine staining were FITC- and PE-conjugated anti IL-2 (MQ1-17H12), anti IL-4 (8D4-8), anti IL-10 (JES3-19F1) and anti IFN-γ (4S.B3), all from BD Pharmingen. Unconjugated anti IL-10 (JES3-19F1) (Pharmingen) and anti TGF-β (R&D Systems) were used for neutralization experiments, anti CD3 (UCHT1) and anti CD28 (CD28.2) for polyclonal activation of T cells.
- Cytokine Assays: T cells were stimulated with allogeneic DC or with platebound anti CD3 (10 μg/ml)+soluble anti CD28 (10 μg/ml) in X-VIVO-20+1% serum. Cytokine analysis was performed at different time points by analysis of supernatants with commercially available ELISA kits for human IL-2, IL-4, IL-10, IFN-γ and TGF-β (BD Pharmingen). For analysis of intracellular cytokine production T cells were either stimulated with
PMA 20 ng/ml and Ca2+ ionophore A23187 500 μg/ml (both from SIGMA) for 6 hours or with platebound anti-CD3 and soluble anti-CD28 Ab for 6 hours. Monensin, 2 μM (SIGMA) was added for the last 4 hours of culture. Cells were collected, washed, fixed and saponine permeabilized (Fix/perm solution, BD Pharmingen) and stained with cytokine specific Ab or isotype. For cytokine mRNA analysis T cells were stimulated with platebound anti CD3 and soluble anti CD28 Ab. Cells were analyzed by RNase Protection assay template sets (BD Pharmingen). - Cell isolation and DC Generation: DC were generated from buffy coats or leukapheresis products (both obtained from the Department of Transfusion medicine from healthy donors after informed consent was given) as described (18,19). In brief, PBMCs were isolated by Ficoll density gradient centrifugation. Monocytes were isolated by plastic adherence and cultured in RPMI Medium, supplemented with IL-4 and GM-CSF. At day 6 a maturation cocktail (IL-1, IL-6, PGE2 and TNFα) was added. At day 7 nonadherent cells were harvested and constituted mature DC that were >90% double positive for costimulatory molecules (CD80, CD86) and CD83.
- CD4+ T cells were isolated from PBMC with a negative CD4+ T cell isolation kit (Miltenyi Biotech). CD4+CD25+ T cells were isolated from the pure, untouched CD4+ T cells using CD25 Microbeads (Miltenyi Biotech). Isolation of CD8+ T cells was performed using a negative CD8+ T cell isolation kit (Miltenyi Biotech). Purity was assessed by FACS.
- Flow Cytometric Analysis: For immunofluorescence staining cells were washed, stained for 20 min at 4° C. with optimal dilution of each Ab. Cells were washed again and analyzed by flow cytometry (FACS Scan™ and CELLQuest™ software; Becton Dickinson). For analysis of cell surface CD152 expression, cells were stained with the appropriate antibody for 2 hours at 37° C.
- Proliferation Assays: To assess proliferation of different CD4+ subtypes 105 sorted T cells were incubated in X-VIVO-20 with different numbers of DC or different concentrations of platebound anti CD3+ soluble anti CD28 in 96-well plates. For assessment of
regulatory properties 105 bulk CD4+ T cells were cultured with 5×103 (in some experiments also with 1×103) DC in 96-well plates. Purified CD4+CD25+ or CD4+CD25− T cells were added at different concentrations. After 4-5 days of culture [3H]Tdr (37 KBq/well) was added for additional 16 h. Proliferation was measured using a liquid scintillation counter. - Transwell Experiments: Transwell experiments were performed in 24-well plates. 106 bulk CD4+ T cells were stimulated with 5×103 DC. In addition, 106 CD4+CD25+ or CD4+CD25− T cells were either added directly to the culture or were placed in Transwell chambers (Millicell, 0.4 μm; Millipore). After 5 days of coculture T cells were transferred to 96-well plates (105 cells/well) in triplicates. Proliferation was measured after 16 h pulse with [3H]Tdr using a liquid scintillation counter.
- A low proliferative potential is highly characteristic of the well characterized regulatory CD25+CD4+ T cells in the murine system (Sakaguchi S. et al., J. Immunol., 155:1151-1164 (1995)). To analyze the proliferative capacity of human CD4+ subpopulations CD4+ T cells were magnetically sorted for their expression of CD25. By using a MACS CD4 negative selection kit and afterwards a positive selection for CD25 a more then 95% pure population of CD4+CD25+ T cells was obtained (
FIG. 1A ). These cells comprised around 6% (2,8-17,2%, n=20) of peripheral CD4+ T cells in the blood of the healthy adults we studied. - Mature DC are known as the most powerful antigen presenting cells (Bancherau, J., Steinman, R. M., Nature, 392:245-252 (1998)). Nevertheless, the CD4+CD25+ T cells exhibited virtually no proliferative response when stimulated in vitro with fully mature allogeneic DC in sharp contrast to the CD4+CD25− T cells (
FIG. 2A , B) or the whole CD4+ population (FIG. 2B ). Interestingly, the CD4+ population depleted of CD25+ T cells showed a higher proliferation when stimulated with allogeneic DC compared to the whole CD4+ population (FIG. 2B ). - It was next determined whether the CD4+CD25+ T cells would possibly only proliferate upon repetitive stimulation by mature DC. After restimulation the proliferative response of CD25− T cells increased somewhat, whereas the response of CD25+ T cells remained very low (
FIG. 2C ). Priming and restimulation by allogeneic mature DC resulted in a 30- to 50-fold expansion of the CD25− population after two rounds of restimulation. In contrast, there was no significant increase of the CD25+population (data not shown). A slightly (˜10%) decreased absolute number of CD4+CD25+ T cells was harvested as compared to the initial inoculum after the repetitive stimulation in the apparent absence of significant apoptosis or necrosis (data not shown). The exceedingly low proliferative response of CD4+CD25+ T cells was also apparent when these cell populations were polyclonally stimulated with platebound anti CD3+ soluble anti CD28 (FIG. 2D ). To test whether the T cell growth factors IL-2 and IL-15 could affect the proliferative potential various doses were added to CD4+CD25+ and CD4+CD25− T cells that were stimulated either with immobilized anti CD3+ soluble anti CD28 (FIG. 2D , upper panels) or with mature allogeneic DC (FIG. 2D , lower panels). A series of pilot experiments revealed that IL-2 enhanced the proliferation of CD25+ T cells only at high doses (100-1000 U/ml). IL-15 had a similar effect, again only at very high doses of 50-100 ng/ml. When both cytokines were mixed, they had strong synergistic effects and doses of 10 U/ml IL-2 plus 10 ng/ml IL-15 were sufficient to promote the proliferation of CD4+CD25+ T cells. The addition of IL-2 and/or IL-15 in the absence of a polyclonal or allogeneic T cell stimulus did not induce significant proliferation in the CD25+ or CD25− T cell subset (data not shown). - To further characterize the CD25+CD4+ T cell population, the expression of various surface molecules on CD4+CD25+, CD4+CD25− was compared with that on stimulated CD4+CD25− T cells (
FIG. 1B ). All three populations showed homogenous expression of CD3 and CD4. No contaminating cells such as monocytes, B cells, CD8+ T cells or NK cells could be observed by FACS analysis (data not shown). Without prior stimulation, i.e. ex vivo the CD25+ population already expressed high levels of intracellular, and low levels of cell surface CTLA-4 (CD152). Ex vivo isolated CD4+CD25+ T cells furthermore constitutively expressed CD122 (IL-2R beta chain), HLA-DR (˜50%) and consisted primarily (˜80%) of CD45RO cells resembling a memory T cell phenotype. In sharp contrast, the ex vivo isolated CD4+CD25− T cells did not express CTLA-4 (neither intracellularly nor on the surface), CD122, or HLA-DR, and more cells expressed CD45RA rather than CD45RO. Following activation with plate bound anti-CD3+ soluble anti-CD28, however, most CD4+CD25− became strongly CD25+ (the level of CD25 expression was about 1 log higher, compared to the CD4+CD25+ T cells, data not shown), and displayed high levels of HLA DR and CD122 (again about 1 log higher compared to CD4+CD25+ T cells) as to be expected. In addition, both intracellular and surface CTLA-4 was upregulated within 24-48 h yet quickly downregulated thereafter (FIG. 1C ) as expected. The kinetics of CTLA-4/CD152 expression proved strikingly different when CD4+CD25+ T cells were stimulated. These cells also upregulated their (constitutively already present albeit low) CD152 surface expression, yet the strong expression of CD152 remained constant for a period of more than 1 week (FIG. 1C ). Staining with several other mAb such as anti CD28, CD62L, CD69, CD95, CD95L, CD154 (CD40L) did not reveal reproducible and significant differences between CD4+CD25+ and CD4+CD25− T cells. - To analyze the putative regulatory properties of CD25+ T cells coculture experiments were performed. In a first series of tests we isolated from a particular donor both the total CD4+ population and the CD25+ and CD25− fractions. Whole CD4+ T cells were then mixed with CD4+CD25+ or CD4+CD25− T cell subpopulations at indicated ratios, and stimulated with allogeneic mature DC (
FIG. 3A ). CD4+CD25+ T cells significantly inhibited the proliferation of whole CD4+ T cells, and at a 1:1 ratio virtually blocked it (cpm then represented the background levels of CD25+ T cell proliferation, seeFIG. 2A -D). The addition of CD25− T cells instead of CD25+ T cells slightly enhanced proliferation (not shown). As CD4+CD25− rapidly expressed CD25 and CD122, i.e. both chains of the IL-2R, upon polyclonal (seeFIG. 1B ) as well stimulation by allogeneic DC (data not shown) this finding indicated that the suppressive activity of the CD4+CD25+ T cell subset was not simply due to consumption or passive adsorption of IL-2 via their IL-2R. CD4+CD25+ T cells exerted also a suppressive activity on whole CD8+ T cells albeit downregulation was less intense (FIG. 3B ). - In a further set of experiments it was determined whether activation of CD4+CD25+ T cells by syngeneic DC was sufficient for induction of their regulatory properties. To this end mature DC and CD4+CD25+ T cells were generated/isolated from the same donor (donor I). In addition, whole CD4+ T cells as well as the CD4+ CD25+ T cell subset were isolated from another donor (donor II). The whole CD4+ T cells (donor II) were then stimulated with allogeneic mature DC (donor I) in the absence (
FIG. 3C , CD4+ only) or presence of various numbers of CD4+CD25+ T cells isolated from either donor I or donor II (FIG. 3C ). Whole CD4+ T cells from donor II proliferated vigorously as expected when stimulated with allogeneic, donor I-derived DC (FIG. 3C , CD4+ only). In the presence of donor I-derived CD4+CD25+ T cells (i.e. syngeneic to the DC used) the proliferation (i.e. alloreactivity) of whole donor II-derived CD4+ T cells was not suppressed at all (FIG. 3C ). Potent suppression occurred, however, when donor II-derived CD4+CD25+ T cells (i.e. allogeneic to the DC used) were added (FIG. 3C ). Suppression was also observed in experiments where DC, whole CD4+ T cells, and CD4+CD25+ T cells were derived from three different donors. These data indicated that TCR-mediated activation of CD4+CD25+ T cells was required to let them exert their regulatory function, and that syngeneic DC were insufficient to induce their suppressive activity. - Next, Transwell chamber experiments were performed to investigate, whether the regulatory function of the CD4+CD25+ T cells was mediated primarily by soluble factors or required cell-cell contact (
FIG. 3D ). As shown inFIG. 3D the CD4+CD25+ T cells suppress proliferation of whole CD4+ T cells almost completely in the presence of allogeneic DC. Separation of the two populations in Transwell chambers virtually abolished their suppressive effect. These observations suggested that direct cell contact is essential for the inhibitory capacity of CD4+CD25+ T cells, as the semipermeable membrane of Transwell chambers allows free passage of soluble factors, but excludes direct cell contact. The Transwell experiments also confirmed that consumption of IL-2 by CD4+CD25+ T cells was not the mechanism responsible for suppression. - Despite the obvious requirement for close interaction between regulatory and responding cells neither a targeting of the antigen-presenting DC or a role of soluble factors was excluded by the Transwell experiments. Therefore, a plate-bound anti-CD3 Ab (in combination with soluble anti CD28 Ab) was also employed as an antigen presenting cell-independent and polyclonal T cell stimulus. Whole CD4+ T cells alone showed strong proliferation upon this stimulation. As mentioned above (
FIG. 2D ) CD4+CD25+ T cells did not proliferate. In coculture of both populations, there was at least a 75% reduction at a 1:1 ratio compared to control (data not shown). These data suggested, that regulation does not primarily occur via modulation of APC function. Neutralizing antibodies to the cytokines IL-10 and TGF-β (critical for the suppressive activities of the so-called Tr1 and Th3, respectively (Groux, H. et al., Nature, 389:737-742 (1997); Fukaura, H. et al., J. Clin. Invest., 98:70-77 (1996)) did not abolish the regulatory activity of the CD4+CD25+ T cells demonstrating that these cytokines played no major suppressive role at least in the assays we looked at. The addition of IL-2 and/or IL-15 to cocultures at the high doses that promote the proliferation of CD4+CD25+ T cells (seeFIG. 2D ) reduced their inhibitory effects. The suppressive activity was, however, likely not abolished as the significant proliferation of the CD4+CD25+ T cells has to be taken into account when interpreting the dataFIG. 3D ). - To analyze and compare the cytokine profiles freshly sorted CD4+CD25+ and CD4+CD25− T cells were activated with plate-bound anti CD3+ anti CD28. Supernatants were then analyzed by ELISA, and RNA expression was studied by RNase protection assays. In addition, intracellular cytokine staining was performed to determine the percentage of cells releasing a certain cytokine. As shown in
FIG. 4 CD4+CD25− T cells predominantly secreted IFN-γ and IL-2, with little secretion of IL-10 and IL-4, resembling a Th1 like profile. CD4+CD25+ T cells on the other hand predominantly produced IL-10 and only low levels of IL-2, IL-4 and IFN-γ, resembling Tr1 cells. Comparison of both subpopulations at the RNA level revealed, that CD25+ T cells express more IL-10, less IFN-γ and similar levels of IL-2 mRNA compared to CD25− T cells. IL-1 receptor antagonist (IL-1 Ra) mRNA was found predominantly in CD4+CD25+ T cells, while significant IL-1, mRNA levels were only present in CD4+CD25− T cells. TGF-β was expressed at similarly low levels in both cell types. - CD4+CD25− and CD4+CD25+ T cells were isolated from whole CD4+ T cells from adult blood by MACS® sorting as described. CD4+CD25+ T cells were divided into three parts. One fraction was activated with 10 μg/ml platebound anti-CD3 and 10 μg/ml soluble anti-CD28 antibodies overnight. Next day this fraction and one part of the non activated CD4+CD25+ T cells were fixed with 2% formaldehyde for 1 hour. The third part was left untreated. Cells were washed three times.
- Unfixed CD4+CD25+ and CD4+CD25− T cells alone and CD4+CD25+ T cells of each fraction, mixed at a 1:1 ratio with CD4+CD25− T cells, were activated with immobilized anti-CD3 and soluble anti-CD28. After 5 days proliferation was measured by [3H]Tdr incorporation. A representative of 5 independent experiments is shown in
FIG. 5 where the symbols represent the following: - CD4+CD25− unfixed CD4+CD25− cells
- CD4+CD25+ unfixed CD4+CD25+ cells
- reg. 1:1 unfixed CD4+CD25+ and CD4+CD25− T cells at a 1:1 ratio
- reg. 1:1
- CD25+ stim fix activated fixed CD4+CD25+ T cells and unfixed CD4+CD25− T cells at a 1:1 ratio
- reg. 1:1
- CD25+ fix non activated fixed CD4+CD25+ T cells and unfixed CD4+CD25− t cells at a 1:1 ratio
Claims (23)
1. Suppressive and/or regulative human CD4+CD25+ T cells.
2. The T cells according to claim 1 which are isolatable from human peripheral blood, preferably by suitable monoclonal antibodies and using magnetic separation or immunoadsorption methods.
3. The cells according to claim 1 which are CTLA-4+ and possess regulatory properties.
4. A method for expanding CD4+CD25+ T cells as defined in claim 1 , which method comprises stimulating the cells with a T cell stimulating agent or with antigen-presenting cells ex vivo and in vivo.
5. The method of claim 4 , wherein the T cell stimulating agent is a composition comprising:
(a) anti-CD3 and/or anti-CD28 ligands/monoclonal antibodies, including superagonistic antibodies;
(b) a ligand/antibody to T cell receptors on the surface of CD4+CD25+ T cells or to T cell receptor components;
(c) MHC-peptide complexes binding to the T cell receptors expressed on the surface of regulatory T cells; or
(d) a phorbolester and a calcium ionophor.
6. The method of claim 4 wherein the antigen-presenting cells are selected from autologous, non-autologous, artificial antigen-presenting cells, etc., preferably the antigen presenting cells are dendritic cells.
7. The method according to claim 4 , wherein the T cell stimulating agent and antigen-presenting cells are used together with IL2 and/or IL-5, IL-7 and/or IL-9, IFN-α and/or IL-10.
8. Expanded human CD4+CD25+ T cells obtainable by the method according to claim 4 .
9. The expanded human CD4+CD25+ T cells of claim 8 which are fixated CD4+CD25+cells, preferably obtainable by ex vivo treatment with paraformaldehyde.
10. A pharmaceutical composition comprising the human CD4+CD25+ T cells according to claim 1 .
11. Use of CD4+CD25+ T cells according to claim 1 for preparing a regulatory medicament.
12. A method to identify, monitor and/or remove CD4+CD25+ T cells from human blood and other tissues ex vivo or in vivo, which method comprises:
(a) utilizing agents/ligands specifically binding to the CD4, and/or CD25, and/or CTL-A4 (CD154) entities on the T cells, preferably anti-CD4 and/or anti-CD25, and/or anti-CTL-A4 antibodies;
(b) utilizing immunoadsorption methods; and/or
(c) utilizing a stimulating agent or antigen presenting cells as defined in claim 4 .
13. Use of a T cell stimulating agent or antigen presenting cells as defined in claim 5 for preparing an agent to induce regulatory CD4+CD25+ T cells in vivo, preferably for preparing an agent for treating autoimmune diseases in a patient.
14. Use of CD4+CD25+ T cells according to claim 1:
(a) in assays that will allow to identify other growth and/or functionally modifying (inhibitory/enhancing)/apoptotic or anti-apoptotic factors;
(b) for identifying molecules expressed by the CD4+CD25+ T cells including identification of novel molecules on said cells, or if presenting molecules which are deemed pharmaceutically active; or
(c) for identifying precursor cells or progeny of the regulatory CD4+CD25+ T cells.
15. Use of the enriched CD4+CD25+ T cells of claim 1 for preparing an agent for adoptive transfer therapy, an agent for treating diseases with enhanced immunity including but not limited to autoimmune diseases, or an agent for preventing/treating transplantation reactions such as graft versus host disease, graft rejections, etc.
16. A method for adoptive transfer therapy which comprises injecting/infusing back into the patients enriched/expanded autologous or non-autologous regulatory CD4+CD25+ T cells according to claim 1 to prevent or treat any immune reactions that are too strong and/or pathogenic, or to prevent/treat transplantation reactions such as graft versus host disease and graft rejections.
17. A method for preparing CD4+CD25+ T cells with a particular desired antigen-specific T cell receptor which comprises:
(a) activating/stimulating/expanding the CD4+CD25+ T cells according to claim 1 with antigen presenting cells, preferably immature or mature dendritic cells (DC), presenting said antigen in vitro or in vivo; or
(b) utilizing a ligand/antibody to a particular T cell receptor expressed on (subsets of) CD4+CD25+ regulatory T cells, or a MHC-peptide Complex binding to a particular T cell receptor on (subsets of) CD4+CD25+ T cells.
18. The method of claim 17 , wherein the antigen-presenting cells are pulsed/loaded/fed with tissue or any defined or undefined antigens, wherein
(a) the defined antigens preferably are autoantigens (including, but not limited to, desmoglein 3 in the case of pemphigus vulgaris, melanA or tyrosinase in case of vitiligo; thyreoglobulin in case of thyreoiditis), foreign antigens (including pathogen-derived antigens such as Hepatitis C), or alloantigens/transplantation antigens; and
(b) the undefined antigens preferably are tissue or cell-derived antigens (including, but not limited to, antigens which are in the form of necrotic or apoptotic cells or tissue derived RNA or hybrids between cells of interest and dendritic cells/antigen presenting cells, other forms of delivery of undefined antigens into dendritic cells or other antigen presenting cells) or pathogen-derived antigens.
19. CD4+CD25+ T cells having a particular desired antigen-specific T cell receptor and being obtainable by the method of claim 17 , or by transfection of a T cell receptor of desired antigen specificity into ex vivo isolated or expanded T cells.
20. Pharmaceutical composition comprising the T cells of claim 19 , preferably said pharmaceutical composition being suitable to treat diseases with enhanced immunity including, but not limited to, autoimmune diseases, graft versus host disease and graft rejections.
21. Use of agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (CD154) entities on the T cells, including but not limited to ligands/antibodies, such as anti-CD25 and/or anti-CTL-A4 mAb, or antibodies or MHC-peptide Complexes or other ligands binding to T cell receptors on (subsets of) CD4+CD25+ T cells for preparing a medicament for removal or functional impairment of CD4+CD25+ T cells in vivo in order to enhance immune responses, including dampen regulation by CD4+CD25+ T cells in vivo, for example, to enhance tumor immunity.
22. Use of the expanded T cells of claim 8 for preparing an agent for adoptive transfer therapy, an agent for treating diseases with enhanced immunity including but not limited to autoimmune diseases, or an agent for preventing/treating transplantation reactions such as graft versus host disease, graft rejections, etc.
23. Use of the fixated T cells of claim 9 for preparing an agent for adoptive transfer therapy, an agent for treating diseases with enhanced immunity including but not limited to autoimmune diseases, or an agent for preventing/treating transplantation reactions such as graft versus host disease, graft rejections, etc.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/661,804 US20050101012A1 (en) | 2001-03-12 | 2003-09-12 | CD4+CD25+ regulatory T cells from human blood |
US13/530,488 US10006901B2 (en) | 2001-03-12 | 2012-06-22 | CD4+CD25+ regulatory T cells from human blood |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE01106033.2 | 2001-03-12 | ||
EP01106033A EP1241249A1 (en) | 2001-03-12 | 2001-03-12 | CD4+CD25+regulatory T cells from human blood |
PCT/EP2002/002671 WO2002072799A1 (en) | 2001-03-12 | 2002-03-12 | Cd4+cd25+ regulatory t cells from human blood |
US10/661,804 US20050101012A1 (en) | 2001-03-12 | 2003-09-12 | CD4+CD25+ regulatory T cells from human blood |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/002671 Continuation WO2002072799A1 (en) | 2001-03-12 | 2002-03-12 | Cd4+cd25+ regulatory t cells from human blood |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/530,488 Continuation US10006901B2 (en) | 2001-03-12 | 2012-06-22 | CD4+CD25+ regulatory T cells from human blood |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050101012A1 true US20050101012A1 (en) | 2005-05-12 |
Family
ID=34553512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/661,804 Abandoned US20050101012A1 (en) | 2001-03-12 | 2003-09-12 | CD4+CD25+ regulatory T cells from human blood |
US13/530,488 Expired - Lifetime US10006901B2 (en) | 2001-03-12 | 2012-06-22 | CD4+CD25+ regulatory T cells from human blood |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/530,488 Expired - Lifetime US10006901B2 (en) | 2001-03-12 | 2012-06-22 | CD4+CD25+ regulatory T cells from human blood |
Country Status (1)
Country | Link |
---|---|
US (2) | US20050101012A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050186207A1 (en) * | 2004-01-08 | 2005-08-25 | The Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
US20050196386A1 (en) * | 2003-04-17 | 2005-09-08 | Bruce Blazar | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US20110086011A1 (en) * | 2008-06-04 | 2011-04-14 | Kasper Lloyd H | Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations |
US8603815B2 (en) | 2002-08-12 | 2013-12-10 | Argos Therapeutics, Inc. | CD4+ CD25− T cells and Tr1-like regulatory T cells |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
US10857177B2 (en) | 2015-08-19 | 2020-12-08 | President And Fellows Of Harvard College | Lipidated PSA compositions and methods |
US11384336B2 (en) | 2016-12-07 | 2022-07-12 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021216738A2 (en) * | 2020-04-21 | 2021-10-28 | Intima Bioscience, Inc. | Compositions and methods of generating an immune response |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721910A (en) * | 1996-06-04 | 1998-02-24 | Exxon Research And Engineering Company | Relational database system containing a multidimensional hierachical model of interrelated subject categories with recognition capabilities |
US5752020A (en) * | 1993-08-25 | 1998-05-12 | Fuji Xerox Co., Ltd. | Structured document retrieval system |
US5950214A (en) * | 1993-11-19 | 1999-09-07 | Aurigin Systems, Inc. | System, method, and computer program product for accessing a note database having subnote information for the purpose of manipulating subnotes linked to portions of documents |
US5991751A (en) * | 1997-06-02 | 1999-11-23 | Smartpatents, Inc. | System, method, and computer program product for patent-centric and group-oriented data processing |
US5991780A (en) * | 1993-11-19 | 1999-11-23 | Aurigin Systems, Inc. | Computer based system, method, and computer program product for selectively displaying patent text and images |
US5999907A (en) * | 1993-12-06 | 1999-12-07 | Donner; Irah H. | Intellectual property audit system |
US6014663A (en) * | 1996-01-23 | 2000-01-11 | Aurigin Systems, Inc. | System, method, and computer program product for comparing text portions by reference to index information |
US6038561A (en) * | 1996-10-15 | 2000-03-14 | Manning & Napier Information Services | Management and analysis of document information text |
US20010003746A1 (en) * | 1998-07-02 | 2001-06-14 | Klaus Sodemann | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
US20010003950A1 (en) * | 1999-12-10 | 2001-06-21 | Delong Zhang | Intermolecularly bound transition element complexes for oxygen-selective adsorption |
US20020090357A1 (en) * | 2000-10-04 | 2002-07-11 | Barrat Franck J. | Regulatory T cells; methods |
US20030005085A1 (en) * | 2001-06-18 | 2003-01-02 | Katsumi Matsuno | Information-processing apparatus, information-processing method, information-processing system, recording medium and program |
US20030014491A1 (en) * | 2001-06-28 | 2003-01-16 | Horvitz Eric J. | Methods for and applications of learning and inferring the periods of time until people are available or unavailable for different forms of communication, collaboration, and information access |
US20030013540A1 (en) * | 2001-07-16 | 2003-01-16 | Penrose Thomas S. | Golf club accessory |
US6534055B1 (en) * | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6803036B1 (en) * | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116741A (en) | 1988-04-12 | 1992-05-26 | Genex Corporation | Biosynthetic uses of thermostable proteases |
DK316989D0 (en) | 1989-06-26 | 1989-06-26 | Novo Nordisk As | ENZYMES |
GB9027836D0 (en) | 1990-12-21 | 1991-02-13 | Unilever Plc | Enzymes and enzymatic detergent compositions |
DE69233628T2 (en) | 1991-07-25 | 2007-04-26 | Biogen Idec Inc., San Diego | Recombinant antibodies for human therapy |
US5567601A (en) | 1993-06-01 | 1996-10-22 | University Of Maryland | Subtilisin mutants lacking a primary calcium binding site |
HUT74222A (en) | 1993-09-15 | 1996-11-28 | Procter & Gamble | Subtilisin bpn' variants with decreased adsorption and increased hydrolysis |
US20020182730A1 (en) * | 1995-07-26 | 2002-12-05 | Micheal L. Gruenberg | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
AU748533B2 (en) | 1997-06-11 | 2002-06-06 | United States Of America As Represented By The Secretary Of The Navy, The | Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses |
US6358506B1 (en) * | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
JP2002534968A (en) | 1999-01-22 | 2002-10-22 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | Activation of regulatory T cells by α-melanocyte stimulating hormone |
EP1241249A1 (en) | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
ATE323151T1 (en) | 2001-05-30 | 2006-04-15 | Fond Telethon | EX-VIVO ISOLATED CD25+CD4+ T CELLS WITH IMMUNOSUPRESSIVE ACTIVITY AND THEIR APPLICATIONS |
-
2003
- 2003-09-12 US US10/661,804 patent/US20050101012A1/en not_active Abandoned
-
2012
- 2012-06-22 US US13/530,488 patent/US10006901B2/en not_active Expired - Lifetime
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534055B1 (en) * | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
US5752020A (en) * | 1993-08-25 | 1998-05-12 | Fuji Xerox Co., Ltd. | Structured document retrieval system |
US5950214A (en) * | 1993-11-19 | 1999-09-07 | Aurigin Systems, Inc. | System, method, and computer program product for accessing a note database having subnote information for the purpose of manipulating subnotes linked to portions of documents |
US5991780A (en) * | 1993-11-19 | 1999-11-23 | Aurigin Systems, Inc. | Computer based system, method, and computer program product for selectively displaying patent text and images |
US5999907A (en) * | 1993-12-06 | 1999-12-07 | Donner; Irah H. | Intellectual property audit system |
US6014663A (en) * | 1996-01-23 | 2000-01-11 | Aurigin Systems, Inc. | System, method, and computer program product for comparing text portions by reference to index information |
US5721910A (en) * | 1996-06-04 | 1998-02-24 | Exxon Research And Engineering Company | Relational database system containing a multidimensional hierachical model of interrelated subject categories with recognition capabilities |
US6038561A (en) * | 1996-10-15 | 2000-03-14 | Manning & Napier Information Services | Management and analysis of document information text |
US5991751A (en) * | 1997-06-02 | 1999-11-23 | Smartpatents, Inc. | System, method, and computer program product for patent-centric and group-oriented data processing |
US6803036B1 (en) * | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
US20010003746A1 (en) * | 1998-07-02 | 2001-06-14 | Klaus Sodemann | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
US20010003950A1 (en) * | 1999-12-10 | 2001-06-21 | Delong Zhang | Intermolecularly bound transition element complexes for oxygen-selective adsorption |
US20020090357A1 (en) * | 2000-10-04 | 2002-07-11 | Barrat Franck J. | Regulatory T cells; methods |
US20030005085A1 (en) * | 2001-06-18 | 2003-01-02 | Katsumi Matsuno | Information-processing apparatus, information-processing method, information-processing system, recording medium and program |
US20030014491A1 (en) * | 2001-06-28 | 2003-01-16 | Horvitz Eric J. | Methods for and applications of learning and inferring the periods of time until people are available or unavailable for different forms of communication, collaboration, and information access |
US20030013540A1 (en) * | 2001-07-16 | 2003-01-16 | Penrose Thomas S. | Golf club accessory |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603815B2 (en) | 2002-08-12 | 2013-12-10 | Argos Therapeutics, Inc. | CD4+ CD25− T cells and Tr1-like regulatory T cells |
US8129185B2 (en) | 2003-04-17 | 2012-03-06 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US20050196386A1 (en) * | 2003-04-17 | 2005-09-08 | Bruce Blazar | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US9181526B2 (en) | 2003-04-17 | 2015-11-10 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US7651855B2 (en) * | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US20100291678A1 (en) * | 2003-04-17 | 2010-11-18 | The Trustees Of The University Of Pennsylvania | Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses |
US7722862B2 (en) | 2004-01-08 | 2010-05-25 | The Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
US20100310588A1 (en) * | 2004-01-08 | 2010-12-09 | The Regents Of The University Of California | Regulatory t cells suppress autoimmunity |
US20050186207A1 (en) * | 2004-01-08 | 2005-08-25 | The Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
US20060233751A1 (en) * | 2004-01-08 | 2006-10-19 | Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
US20110086011A1 (en) * | 2008-06-04 | 2011-04-14 | Kasper Lloyd H | Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations |
US8586029B2 (en) * | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
US10857177B2 (en) | 2015-08-19 | 2020-12-08 | President And Fellows Of Harvard College | Lipidated PSA compositions and methods |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
US11384336B2 (en) | 2016-12-07 | 2022-07-12 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells |
Also Published As
Publication number | Publication date |
---|---|
US20120328563A1 (en) | 2012-12-27 |
US10006901B2 (en) | 2018-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1379625B1 (en) | Cd4+cd25+ regulatory t cells from human blood | |
AU2002257648A1 (en) | CD4+CD25+ regulatory T cells from human blood | |
Dieckmann et al. | Ex vivo isolation and characterization of CD4+ CD25+ T cells with regulatory properties from human blood | |
US10006901B2 (en) | CD4+CD25+ regulatory T cells from human blood | |
Bisikirska et al. | TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+ CD25+ Tregs | |
Boussiotis et al. | IL-10–producing T cells suppress immune responses in anergic tuberculosis patients | |
Kuwana et al. | Induction of antigen‐specific human CD4+ T cell anergy by peripheral blood DC2 precursors | |
Zheng et al. | CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome | |
Demeure et al. | Human naive CD4 T cells produce interleukin‐4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions | |
Gallon et al. | Differential effects of calcineurin and mammalian target of rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells | |
CA2413866C (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations | |
US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
AU2006232374A1 (en) | Preventing rejection of transplanted tissue using regulatory T cells | |
Martinez et al. | CD30 EXPRESSION IDENTIFIES A FUNCTIONAL ALLOREACTIVE HUMAN T-LYMPHOCYTE SUBSET1 | |
Karakhanova et al. | Highly efficient expansion of human CD4+ CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease | |
JP2007175062A (en) | Use of cytokine, cell and mitogen to inhibit graft versus host disease | |
Burt et al. | Circulating HLA-DR+ natural killer cells have potent lytic ability and weak antigen-presenting cell function | |
AU2011203204A1 (en) | CD4+CD25+ regulatory T cells from human blood | |
EP1391504A1 (en) | CD4+ CD25- T cells and Tr1-like regulatory T cells | |
Chen et al. | Porcine-Stimulated Human Tr1 Cells Showed Enhanced Suppression in Xenoantigen Stimulation Response | |
EP1391210A2 (en) | Regulatory medicament comprising CD4+CD25- T cells and Tr1-like regulatory cells | |
Di Genova | Vaccination and immunological memory | |
JP2017509343A (en) | Treatment of inflammatory and inappropriate immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARGOS THERAPEUTICS, INC., NORTH CAROLINA Free format text: CHANGE OF NAME;ASSIGNOR:MERIX BIOSCIENCE, INC.;REEL/FRAME:018912/0269 Effective date: 20041014 |
|
AS | Assignment |
Owner name: ARGOS THERAPEUTICS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GEROLD SCHULER, M.D.;REEL/FRAME:018910/0879 Effective date: 20020801 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |